Novartis: may divest eye care franchises

(CercleFinance.com) - Novartis has begun negotiations to divest part of its ophthalmology franchise, according to Bloomberg.


Invest Securities said that the group has reportedly approached potential bidders through an adviser for the sale of its front-of-the-eye portfolio, with the aim of focusing on growth segments.

The portfolio would include the dry eye disease treatment Xiidra, but excludes the age-related macular degeneration drug Lucentis, the news agency adds.

Harrow announced last December that it had reached an agreement to acquire the US commercial rights to five Novartis ophthalmology products.


Copyright (c) 2023 CercleFinance.com. All rights reserved.